Media coverage about Leap Therapeutics (NASDAQ:LPTX) has trended somewhat negative this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Leap Therapeutics earned a news impact score of -0.01 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1508118876402 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of LPTX stock opened at $8.90 on Monday. The stock has a market capitalization of $129.06, a PE ratio of -2.69 and a beta of -0.42. Leap Therapeutics has a 52-week low of $4.90 and a 52-week high of $10.01.
Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings results on Friday, February 23rd. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. analysts predict that Leap Therapeutics will post -2.52 earnings per share for the current year.
WARNING: “Somewhat Negative Media Coverage Somewhat Unlikely to Impact Leap Therapeutics (LPTX) Share Price” was published by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3343421/somewhat-negative-media-coverage-somewhat-unlikely-to-impact-leap-therapeutics-lptx-share-price.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.